Page last updated: 2024-11-05

spectinomycin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Spectinomycin is a broad-spectrum antibiotic that is effective against a variety of Gram-negative bacteria, including Neisseria gonorrhoeae and Haemophilus influenzae. It is typically administered by intramuscular injection and is not absorbed well orally. Spectinomycin is a synthetically produced compound that is structurally similar to aminoglycosides. It works by inhibiting protein synthesis in bacteria, specifically by binding to the 30S ribosomal subunit. Spectinomycin is used to treat a variety of infections, including gonorrhea, urethritis, and pelvic inflammatory disease. It is also sometimes used to treat infections in patients who are allergic to penicillin. Spectinomycin is a relatively safe drug, but it can cause side effects such as nausea, vomiting, and diarrhea. It is important to note that spectinomycin resistance is becoming increasingly common, so it is important to use this drug judiciously. Spectinomycin is studied for its potential to combat resistant bacterial strains and to understand its mechanisms of action in bacterial cells.'

Spectinomycin: An antibiotic produced by Streptomyces spectabilis. It is active against gram-negative bacteria and used for the treatment of GONORRHEA. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

spectinomycin dihydrochloride : A hydrochloride obtained by combining spectinomycin with two molar equivalents of hydrochloric acid. An antibiotic that is active against gram-negative bacteria and used (as its pentahydrate) to treat gonorrhea. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

spectinomycin : A pyranobenzodioxin and antibiotic that is active against gram-negative bacteria and used (as its dihydrochloride pentahydrate) to treat gonorrhea. It is produced by the bacterium Streptomyces spectabilis. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID15541
CHEMBL ID1167
CHEBI ID9215
SCHEMBL ID3533
MeSH IDM0000292

Synonyms (111)

Synonym
AC-13570
u-18409e
spectinomycin hydrochloride
unii-93aki1u6qf
4h-pyrano(2,3-b)(1,4)benzodioxin-4-one, decahydro-4a,7,9-trihydroxy-2-methyl-6,8-bis(methylamino)-, (2r,4ar,5ar,6s,7s,8r,9s,9ar,10as)-
93aki1u6qf ,
AB00642548-10
KBIO1_000137
DIVK1C_000137
(2r,4ar,5ar,6s,7s,8r,9s,9ar,10as)-4a,7,9-trihydroxy-2-methyl-6,8-bis(methylamino)decahydro-4h-pyrano[2,3-b][1,4]benzodioxin-4-one
SPECTRUM_000954
BSPBIO_000667
4h-pyrano(2,3-b)(1,4)benzodioxin-4-one, decahydro-4a,7,9-trihydroxy-2-methyl-6,8-bis(methylamino)-
m-141
actinospectacina [italian]
einecs 216-911-3
spectinomycinum [inn-latin]
u 18409 e
spectinomicina [italian]
spectinomycin [inn:ban]
brn 2171701
espectinomicina [inn-spanish]
spectinomycine [inn-french]
SMP1_000276
4h-pyrano[2,3-b][1,4]benzodioxin-4-one, decahydro-4a,7,9-trihydroxy-2-methyl-6,8-bis(methylamino)-, (2r,4ar,5ar,6s,7s,8r,9s,9ar,10as)-
antibiotic 2233wp
spectam
(2r,4ar,5ar,6s,7s,8r,9s,9ar,10as)-4a,7,9-trihydroxy-2-methyl-6,8-bis(methylamino)-3,5a,6,7,8,9,9a,10a-octahydro-2h-benzo[[?]]pyrano[[?]][1,4]dioxin-4-one
togamycin
m 141
22189-32-8
espectinomicina
PRESTWICK3_000804
BPBIO1_000735
spectinomycin
trobicin
u 18409
actinospectacin
xk 43-1
spectinomycin dihydrochloride
1695-77-8
C02078
SCM ,
DB00919
NCGC00142531-01
KBIOSS_001434
KBIO2_001434
KBIO3_001816
KBIO2_004002
KBIO2_006570
NCI60_000023
KBIOGR_001425
SPECTRUM2_001315
SPECTRUM3_000898
PRESTWICK1_000804
PRESTWICK0_000804
NINDS_000137
SPBIO_002588
SPECTRUM4_000993
SPBIO_001409
SPECTRUM5_001407
IDI1_000137
PRESTWICK2_000804
NCGC00142531-02
HMS2089C03
CHEMBL1167
chx-3101
adspec
prospec
chebi:9215 ,
adspec (tn)
prospec (tn)
spectinomycin (inn)
spcm
D08526
actinospectacina
spectinomycinum
spectinomycine
AKOS015961272
NCGC00017354-03
NCGC00017354-02
NCGC00017354-04
spectinomycin hcl/ sulphate
spectinomycin [mi]
spectinomycin [inn]
spectinomycin [who-dd]
spectinomycin [green book]
spectinomycin [mart.]
(2r-(2.alpha.,4a.beta.,5a.beta.,6.beta.,7.beta.,8.beta.,9.alpha.,9a.alpha.,10a.beta.))-decahydro-4a,7,9-trihydroxy-2-methyl-6,8-bis(methylamino)-4h-pyrano(2,3-b)(1,4)benzodioxin-4-one
spectinomycin [vandf]
CCG-208273
SCHEMBL3533
AB00642548-11
ethyl2-anilino-4-chloro-5-formyl-3-thiophenecarboxylate
AB00642548_12
AB00642548_13
DTXSID9023592
(1r,3s,5r,8r,10r,11s,12s,13r,14s)-8,12,14-trihydroxy-5-methyl-11,13-bis(methylamino)-2,4,9-trioxatricyclo[8.4.0.0^{3,8}]tetradecan-7-one
SR-05000001868-4
sr-05000001868
u18409
gtpl11127
u-18409
SBI-0051514.P003
actinospectacin; espectinomicina; chx-3101
Q416154
(1r,3s,5r,8r,10r,11s,12s,13r,14s)-8,12,14-trihydroxy-5-methyl-11,13-bis(methylamino)-2,4,9-trioxatricyclo[8.4.0.03,8]tetradecan-7-one
A878657
(2r,4ar,5ar,6s,7s,8r,9s,9ar,10as)-4a,7,9-trihydroxy-2-methyl-6,8-bis(methylamino)octahydro-2h-benzo[b]pyrano[2,3-e][1,4]dioxin-4(3h)-one
HY-B1828
CS-0013897

Research Excerpts

Overview

Spectinomycin is a broad-spectrum aminocyclitol antibiotic that is highly effective in the treatment of uncomplicated gonorrhea. It is an important addition to gonorrhoea therapy but should be reserved for penicillin sensitive patients andPenicillin insensitive infections.

ExcerptReferenceRelevance
"Spectinomycin is a dioxane-bridged, tricyclic aminoglycoside produced by "( Dioxane Bridge Formation during the Biosynthesis of Spectinomycin Involves a Twitch Radical
Chen, Y; Chen, Z; Hou, X; Ko, Y; Liu, HW; Ruszczycky, MW; Zhang, J; Zhou, J, 2022
)
2.41
"Spectinomycin is a ribosome-binding antibiotic that blocks the translocation step of translation. "( Structural Recognition of Spectinomycin by Resistance Enzyme ANT(9) from Enterococcus faecalis.
Kanchugal P, S; Selmer, M, 2020
)
2.3
"Spectinomycin is an aminoglycoside antibiotic composed of actinamine and actinospectose, which are fused together by a putative glycosyltransferase, SpcG, during spectinomycin biosynthesis. "( Heterologous production of spectinomycin in Streptomyces venezuelae by exploiting the dTDP-D-desosamine pathway.
Jha, AK; Lamichhane, J; Pandey, RP; Singh, B; Sohng, JK, 2014
)
2.14
"Spectinomycin is an aminocyclitol antibiotic used clinically to treat a variety of infections in animals. "( Characterization of Spectinomycin Resistance in Streptococcus suis Leads to Two Novel Insights into Drug Resistance Formation and Dissemination Mechanism.
Huang, K; Jin, M; Song, Y; Xiao, J; Zhang, A; Zhang, Q; Zhang, Z, 2016
)
2.2
"Spectinomycin is a broad-spectrum aminocyclitol antibiotic that is highly effective in the treatment of uncomplicated gonorrhea. "( Spectinomycin.
Holloway, WJ, 1982
)
3.15
"Spectinomycin is an important addition to gonorrhoea therapy but should be reserved for penicillin sensitive patients and penicillin insensitive infections."( Sectinomycin in the treatment of gonorrhoea in females and males.
Finger, AH, 1975
)
0.98
"Spectinomycin is an aminocyclitol antibiotic, but different in chemical structure from other aminocyclitol antibiotics such as streptomycin, kanamycin and gentamicin. "( [Ototoxicity of spectinomycin (author's transl)].
Akiyoshi, M; Ikeda, T; Yano, S, 1976
)
2.04
"Spectinomycin appears to be an acceptable alternative therapy."( Antibiotic sensitivities of Neisseria gonorrhoeae in the Toronto area.
Givan, KF; Keyl, A, 1974
)
0.97

Effects

Spectinomycin has been proven to be highly effective in the intramuscular single-dose treatment of gonorrhea. It has consequently become widely used in treating these infections.

ExcerptReferenceRelevance
"Spectinomycin clinically has been proven to be highly effective in the intramuscular single-dose treatment of gonorrhea."( [Ototoxicity of spectinomycin (author's transl)].
Akiyoshi, M; Ikeda, T; Yano, S, 1976
)
1.32
"Spectinomycin has consequently become widely used in treating these infections."( Plasmid profile of Neisseria gonorrhoeae in Nigeria and efficacy of spectinomycin in treating gonorrhoea.
Johnston, NA; Ochei, J; Ogunbanjo, BO; Osoba, AO, 1987
)
1.23

Actions

ExcerptReferenceRelevance
"Spectinomycin displays a dose-dependent neuromuscular blocking activity in vivo. "( The neuromuscular blocking activity of spectinomycin on the rat sciatic nerve-gastrocnemius muscle preparation.
Cagiano, R; Cuomo, V; Fiore, T; Renna, G, 1986
)
1.98

Treatment

Spectinomycin-treatment of wild-type plants phenocopies the molecular phenotype of plastid proteome accumulation in tic56-1 and to a smaller degree also ppi2 plastids. Treatment with spectinomycin or rifampin blocked appearance of insensitive cells and increased susceptibility to colicin E1.

ExcerptReferenceRelevance
"Spectinomycin-treatment of wild-type plants phenocopies the molecular phenotype of plastid proteome accumulation in tic56-1 and to a smaller degree also ppi2 plastids, suggesting that a defect in plastid translation is largely responsible for the phenotype of both import mutants."( Importance of Translocon Subunit Tic56 for rRNA Processing and Chloroplast Ribosome Assembly.
Agne, B; Baginsky, S; Helm, S; Köhler, D, 2016
)
1.16
"Treatment with spectinomycin or rifampin blocked appearance of insensitive cells and even increased susceptibility to colicin E1."( Outer membrane-dependent transport systems in Escherichia coli: effect of repression or cessation of colicin receptor synthesis on colicin receptor activities.
Kadner, RJ; McElhaney, G, 1980
)
0.6
"Treatment with spectinomycin resulted in a 98% cure rate 14 days after treatment."( Treatment of chancroid with a single dose of spectinomycin.
Bernal, M; Guzmán, J; Guzmán, M,
)
0.73

Toxicity

ExcerptReferenceRelevance
" Adverse drug experiences reported by subjects included nausea, dizziness, light-headedness, diaphoresis, costal pain, and perioral numbness."( Human safety and pharmacokinetics of a single intramuscular dose of a novel spectinomycin analog, trospectomycin (U-63,366F).
Bye, A; Francom, SF; Novak, E; Patel, R; Paxton, LM; Zurenko, GE, 1990
)
0.51
" Investigational toxicology methods, using appropriate models and hypotheses, can often resolve problems, identify toxic chemical substituents and salvage therapeutic discovery programs."( Cultured hepatocytes as investigational models for hepatic toxicity: practical applications in drug discovery and development.
Bacon, JA; Cramer, CT; Peng, GW; Petrella, DK; Stryd, RP; Sun, EL; Ulrich, RG, 1995
)
0.29
" PipX is thus deduced to be a toxic protein, but its toxicity has not been clearly defined because of the lack of P(II)-deficient mutants carrying wild-type pipX."( Evaluation of the effects of P(II) deficiency and the toxicity of PipX on growth characteristics of the P(II)-Less mutant of the cyanobacterium Synechococcus elongatus.
Aichi, M; Chang, Y; Maeda, S; Omata, T; Takatani, N, 2013
)
0.39

Pharmacokinetics

spectinomycin is found to be on par with its profile in other mammalian species including humans. A pharmacokinetic and bioavailability study was conducted in healthy broiler chickens following administration of a single (50 mg/kg bw) intravenous injection.

ExcerptReferenceRelevance
" Pharmacokinetic calculations based on data obtained by high-performance liquid chromatography showed that after a 1,000-mg intramuscular dose of trospectomycin (3."( Human safety and pharmacokinetics of a single intramuscular dose of a novel spectinomycin analog, trospectomycin (U-63,366F).
Bye, A; Francom, SF; Novak, E; Patel, R; Paxton, LM; Zurenko, GE, 1990
)
0.51
"Two interactive computer programs, INTRAV and ORAL, were written to permit pharmacokinetic modeling of experimental data and to obtain pertinent values based on derived estimates."( INTRAV and ORAL: BASIC interactive computer programs for estimating pharmacokinetic parameters.
Hunter, S; Valentine, JL, 1985
)
0.27
"A pharmacokinetic and bioavailability study of spectinomycin was conducted in healthy broiler chickens following administration of a single (50 mg/kg bw) intravenous (i."( Pharmacokinetics and bioavailability of spectinomycin after i.v., i.m., s.c. and oral administration in broiler chickens.
Abu-Basha, EA; Albwa'neh, SJ; Gehring, R, 2007
)
0.86
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
"Following intravenous (IV) administration, the pharmacokinetics of spectinomycin in rats was found to be on par with its profile in other mammalian species including humans with respect to its overall excretion and half-life at effective concentrations."( Pharmacokinetic profile of spectinomycin in rats.
Lee, R; Madhura, DB; Meibohm, B, 2013
)
0.92
" Pharmacodynamic models describing the relationship between the concentration of antimicrobials and the minimum growth rate of the bacteria provide more detailed information than the MIC only."( Time-kill curve analysis and pharmacodynamic modelling for in vitro evaluation of antimicrobials against Neisseria gonorrhoeae.
Althaus, CL; Foerster, S; Hathaway, LJ; Low, N; Unemo, M, 2016
)
0.43
" The experimental time-kill curves were analysed and quantified with a previously established pharmacodynamic model."( Time-kill curve analysis and pharmacodynamic modelling for in vitro evaluation of antimicrobials against Neisseria gonorrhoeae.
Althaus, CL; Foerster, S; Hathaway, LJ; Low, N; Unemo, M, 2016
)
0.43
" gonorrhoeae time-kill curve experiments analysed with a pharmacodynamic model have potential for in vitro evaluation of new and existing antimicrobials."( Time-kill curve analysis and pharmacodynamic modelling for in vitro evaluation of antimicrobials against Neisseria gonorrhoeae.
Althaus, CL; Foerster, S; Hathaway, LJ; Low, N; Unemo, M, 2016
)
0.43
" Drug concentrations were measured by LC-MS/MS and analyzed by noncompartmental pharmacokinetic analysis."( Comparative pharmacokinetics of spectinamide 1599 after subcutaneous and intrapulmonary aerosol administration in mice.
Braunstein, M; Gonzalez-Juarrero, M; Hickey, A; Lee, RE; Lenaerts, AJ; Lukka, PB; Meibohm, B; Rathi, C; Wagh, S, 2019
)
0.51

Compound-Compound Interactions

ExcerptReferenceRelevance
"The in vitro effects of spectinomycin and ceftriaxone, alone or in combination with erythromycin, ofloxacin, and doxycycline, against Chlamydia trachomatis were investigated by the checkerboard method and compared by Ridit (reference identical unit) analysis."( In vitro effects of spectinomycin and ceftriaxone alone or in combination with other antibiotics against Chlamydia trachomatis.
Gong, X; Mabey, D; Shang, S; Wang, Q; Xia, L; Zhang, J; Zhao, J; Zhong, M, 2005
)
0.96

Bioavailability

ExcerptReferenceRelevance
"A pharmacokinetic and bioavailability study of spectinomycin was conducted in healthy broiler chickens following administration of a single (50 mg/kg bw) intravenous (i."( Pharmacokinetics and bioavailability of spectinomycin after i.v., i.m., s.c. and oral administration in broiler chickens.
Abu-Basha, EA; Albwa'neh, SJ; Gehring, R, 2007
)
0.86

Dosage Studied

Spectinomycin hydrochloride in the dosage used rarely eliminated C. difficile. It prolonged the subclinical incubation period. The highest serum concentration was achieved after one hour post each intramuscular dose.

ExcerptRelevanceReference
" This dosage of spectinomycin did not prevent the development of syphilitic orchitis or reactivity to the FTA-ABS test, but it prolonged the subclinical incubation period."( Effect of spectinomycin on T. pallidum in incubating experimental syphilis.
Petzoldt, D, 1975
)
1
" In the dosage used for gonococcal infections, spectinomycin has little effect on infection with Treponema pallidum."( Drugs five years later. Spectinomycin.
Finland, M; McCormack, WM, 1976
)
0.82
"These recommendations specify appropriate treatment, including dosage of antibiotics for uncomplicated gonococcal infections in adults, infections with penicillinase-producing Neisseria gonorrhoeae, acute salpingitis, acute epididymitis, disseminated gonococcal infections, and gonococcal infections in pediatric patients (including neonatal infections)."( Gonorrhea. Center for Disease Control recommended treatment schedules, 1979.
, 1979
)
0.26
" An intermediate category was proposed for MICs greater than 2-4 micrograms/m (28-32 mm) pending more clinical experience with higher and/or prolonged cefmetazole dosing regimens."( Cefmetazole and trospectomycin in vitro susceptibility testing interpretive criteria and quality control guidelines for Neisseria gonorrheae.
Erwin, ME; Gerlach, EH; Jones, RN; Koontz, FP; Murray, PR; Washington, JA,
)
0.13
" dosing was rapid."( Pharmacokinetics of trospectomycin sulphate in healthy subjects after single intravenous and intramuscular doses.
Bye, A; Nichols, DJ; Novak, E, 1991
)
0.28
" dosing was only approximately 75% but there were few other biologically significant differences between the routes of administration."( Pharmacokinetics and fate of 3H-trospectomycin sulphate, a novel aminocyclitol antibiotic, in male and female rats.
Burrows, M; Bye, A; Constable, DA; Dring, LG; Jeffrey, P; Nichols, DJ, 1991
)
0.28
" The implications of dose-response curves are discussed on the basis of the receptor site concept for drug action."( Quantification of antibiotic drug potency by a two-compartment radioassay of bacterial growth.
Boonkitticharoen, V; Ehrhardt, JC; Kirchner, PT, 1990
)
0.28
" Rats were treated for 30 or 90 days with 0, 50, or 250 mg/kg/day of trospectomycin sulfate prior to being killed, and another group was dosed for 90 days and then allowed to recover for 79 days prior to sacrifice."( Reversible, hepatic, lysosomal phospholipidosis in rat induced by subchronic daily administration of trospectomycin sulfate.
Cox, JW; Epps, DE; Ginsberg, LC; Larsen, ER; McKenna, R; Ulrich, RG; Wynalda, MA, 1989
)
0.28
" We concluded that rosoxacin at a dosage of 300 mg administered orally was fairly effective in the treatment of gonococcal urethritis in men caused by both PPNG and non-PPNG strains."( Rosoxacin in the treatment of uncomplicated gonorrhoea in men.
Ariyarit, C; Chitwarakorn, A; Panikabutra, K; Saensanoh, C, 1984
)
0.27
" The highest serum concentration of spectinomycin was achieved after one hour post each intramuscular dose during multiple dosage regimen."( Serum concentrations and tissue residues of spectinomycin in chickens.
el-Aziz, MI; el-Din, HS; el-Komy, AA; el-Sayed, MG, 1995
)
0.83
"0 microg/ml), and milk from cows dosed with spectinomycin."( Confirmation of spectinomycin in milk using ion-pair solid-phase extraction and liquid chromatography-electrospray ion trap mass spectrometry.
Carson, MC; Heller, DN, 1998
)
0.91
" In order to ensure full cure, all gonorrhoea patients should be followed-up after a single dosage of any antibiotic."( Clinical efficacy of the various drugs used in the treatment of gonorrhoeae.
Akhter, K; Khan, A,
)
0.13
" Increasing the dosage regimen can be applied to ceftriaxone and azithromycin, but the emergence of high-level resistance has already been reported."( New treatment options for infections caused by increasingly antimicrobial-resistant Neisseria gonorrhoeae.
Chong, Y; Lee, H; Lee, K, 2016
)
0.43
" Urinary and fecal excretion was monitored throughout the dosing period."( Tissue Penetration of a Novel Spectinamide Antibiotic for the Treatment of Tuberculosis.
Boyd, VA; Jeffries, C; Lee, RE; Liu, J; Loveless, V; Madhura, DB; Meibohm, B; Trivedi, A, 2016
)
0.43
" The pharmacodynamic parameters based on a wide range of concentrations below and above the MIC provide information that could support improving future dosing strategies to treat gonorrhoea."( Time-kill curve analysis and pharmacodynamic modelling for in vitro evaluation of antimicrobials against Neisseria gonorrhoeae.
Althaus, CL; Foerster, S; Hathaway, LJ; Low, N; Unemo, M, 2016
)
0.43
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
antimicrobial agentA substance that kills or slows the growth of microorganisms, including bacteria, viruses, fungi and protozoans.
bacterial metaboliteAny prokaryotic metabolite produced during a metabolic reaction in bacteria.
antibacterial drugA drug used to treat or prevent bacterial infections.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (6)

ClassDescription
cyclic hemiketalA hemiacetal having the structure R2C(OH)OR (R =/= H), derived from a ketone by formal addition of an alcohol to the carbonyl group. The term 'cyclic hemiketals', once abandoned by IUPAC, has been reinstated as a subclass of hemiacetals.
cyclic acetalAn acetal in the molecule of which the acetal carbon and one or both oxygen atoms thereon are members of a ring.
cyclic ketone
secondary amino compoundA compound formally derived from ammonia by replacing two hydrogen atoms by organyl groups.
pyranobenzodioxinAny organic heterotricyclic compound whose core skeleton consists of a benzodioxin ring that is ortho-fused to a pyran ring.
secondary alcoholA secondary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has two other carbon atoms attached to it.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
Spectinomycin Action Pathway14

Protein Targets (1)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency3.54810.003245.467312,589.2998AID2517
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (242)

Assay IDTitleYearJournalArticle
AID1182152Ratio of MIC99 for Mycobacterium smegmatis to ratio of MIC99 for Mycobacterium smegmatis in presence of chlorpromazine-N-oxide2014Bioorganic & medicinal chemistry, Aug-15, Volume: 22, Issue:16
Pharmacologically active metabolites, combination screening and target identification-driven drug repositioning in antituberculosis drug discovery.
AID212742Inhibition of purified telomerase of Euplotes aediculatus at 50 uM2004Bioorganic & medicinal chemistry letters, Jul-05, Volume: 14, Issue:13
Nucleic acid-binding ligands identify new mechanisms to inhibit telomerase.
AID530840Antimicrobial activity against penicillin-,ofloxacin- and tetracyclin-resistant Neisseria gonorrhoeae multiantigen sequence type 835 isolate 5 harboring penA gene by Etest2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Ceftibuten resistance and treatment failure of Neisseria gonorrhoeae infection.
AID584327Antibacterial activity against speE deficient Escherichia coli JW0117-12010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Interplay between drug efflux and antioxidants in Escherichia coli resistance to antibiotics.
AID65059Concentration required for half maximum rate of enhanced [3H]DHS uptake in Escherichia coli K121987Journal of medicinal chemistry, Feb, Volume: 30, Issue:2
Comparison of aminoglycoside antibiotics with respect to uptake and lethal activity in Escherichia coli.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID509631Antimicrobial activity against Staphylococcus aureus RN4220 transformant carrying plasmid pKKS25 and expressing erm(T), dfrK and tet(L) genes by broth microdilution method2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Identification of a plasmid-borne resistance gene cluster comprising the resistance genes erm(T), dfrK, and tet(L) in a porcine methicillin-resistant Staphylococcus aureus ST398 strain.
AID530839Antimicrobial activity against penicillin-,ofloxacin- and tetracyclin-resistant Neisseria gonorrhoeae multiantigen sequence type 835 isolate 4 harboring penA gene by Etest2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Ceftibuten resistance and treatment failure of Neisseria gonorrhoeae infection.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1182138Antitubercular activity against Mycobacterium smegmatis assessed as reduction in MIC99 by checkerboard assay in presence of chlorpromazine-N-S-dioxide relative to control2014Bioorganic & medicinal chemistry, Aug-15, Volume: 22, Issue:16
Pharmacologically active metabolites, combination screening and target identification-driven drug repositioning in antituberculosis drug discovery.
AID1182137Antitubercular activity against Mycobacterium smegmatis assessed as reduction in MIC99 by checkerboard assay in presence of chlorpromazine sulfoxide relative to control2014Bioorganic & medicinal chemistry, Aug-15, Volume: 22, Issue:16
Pharmacologically active metabolites, combination screening and target identification-driven drug repositioning in antituberculosis drug discovery.
AID1548178Anti-chlamydial activity against Chlamydia trachomatis Serovar LGV-L2 infected in Hep2 cells assessed as reduction in chlamydial inclusion growth by measuring appearance of small and irregular inclusions at 128 ug/ml treated at 8 hrs post-infection and 242020Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8
Synthesis and Antichlamydial Activity of Molecules Based on Dysregulators of Cylindrical Proteases.
AID279870Antimicrobial activity against Burkholderia pseudomallei KHW in presence of 15.6 uM prochlorperazine2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Synergistic interaction between phenothiazines and antimicrobial agents against Burkholderia pseudomallei.
AID1743164Antibacterial activity against Staphylococcus aureus2020European journal of medicinal chemistry, Dec-15, Volume: 208Multiple biological active 4-aminopyrazoles containing trifluoromethyl and their 4-nitroso-precursors: Synthesis and evaluation.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID325443Antibacterial activity against Escherichia coli K10 after 14 to 16 hrs by broth dilution method2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Polyamine effects on antibiotic susceptibility in bacteria.
AID322558Antibacterial activity against Pasteurella multocida isolate 4 with operon A,B,C,D,E,F 16S rRNA C1192G transversion mutation by CLSI M31-A2 method2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Mutations in 16S rRNA and ribosomal protein S5 associated with high-level spectinomycin resistance in Pasteurella multocida.
AID530052Antimicrobial activity against Staphylococcus aureus RN4220 expressing gyrB D437N mutant gene by broth microdilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Discovery and characterization of QPT-1, the progenitor of a new class of bacterial topoisomerase inhibitors.
AID322560Antibacterial activity against Pasteurella multocida isolate 6 with operon A,B,C,D,E 16S rRNA C1192G transversion mutation by CLSI M31-A2 method2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Mutations in 16S rRNA and ribosomal protein S5 associated with high-level spectinomycin resistance in Pasteurella multocida.
AID279901Antimicrobial activity against Burkholderia pseudomallei KHW in presence of 62.5 uM chlorpromazine2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Synergistic interaction between phenothiazines and antimicrobial agents against Burkholderia pseudomallei.
AID1182141Antitubercular activity against Mycobacterium smegmatis by checkerboard assay in presence of chlorpromazine-N-oxide2014Bioorganic & medicinal chemistry, Aug-15, Volume: 22, Issue:16
Pharmacologically active metabolites, combination screening and target identification-driven drug repositioning in antituberculosis drug discovery.
AID1453425Antibacterial activity against Neisseria gonorrhoeae NCTC 8375/ATCC 19424 by two-fold serial dilution method2017Bioorganic & medicinal chemistry letters, 07-01, Volume: 27, Issue:13
Synthesis and biological evaluation of novel 5-aryl-4-(5-nitrofuran-2-yl)-pyrimidines as potential anti-bacterial agents.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID322565Antibacterial activity against Pasteurella multocida isolate 11 with operon B,C 16S rRNA C1192G transversion mutation and S5 protein 32-SF-33>32I mutation by CLSI M31-A2 method2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Mutations in 16S rRNA and ribosomal protein S5 associated with high-level spectinomycin resistance in Pasteurella multocida.
AID1182140Antitubercular activity against Mycobacterium smegmatis by checkerboard assay in presence of 7-hydroxy chlorpromazine2014Bioorganic & medicinal chemistry, Aug-15, Volume: 22, Issue:16
Pharmacologically active metabolites, combination screening and target identification-driven drug repositioning in antituberculosis drug discovery.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID279873Antimicrobial activity against Burkholderia pseudomallei KHW in presence of 1000 uM promazine2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Synergistic interaction between phenothiazines and antimicrobial agents against Burkholderia pseudomallei.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1241204Inhibition of pre-miR-21 (unknown origin) cleavage assessed as reduction of oncogenic microRNAs biogenesis at 200 uM by measuring fluorescence every minute for 5 hrs using 5'-FAM,3'-dabcyl-pre-miRNA beacons by FRET assay in presence of recombinant Dicer2015Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17
Ribosome-targeting antibiotics as inhibitors of oncogenic microRNAs biogenesis: Old scaffolds for new perspectives in RNA targeting.
AID325445Antibacterial activity against Escherichia coli C921-61 after 14 to 16 hrs by broth dilution method2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Polyamine effects on antibiotic susceptibility in bacteria.
AID322564Antibacterial activity against Pasteurella multocida isolate 10 with operon B,C 16S rRNA C1192G transversion mutation and S5 protein 32-SF-33>32I mutation by CLSI M31-A2 method2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Mutations in 16S rRNA and ribosomal protein S5 associated with high-level spectinomycin resistance in Pasteurella multocida.
AID534343Antimicrobial activity against Burkholderia pseudomallei Bp173 harboring mini-Tn7T after 24 hrs by broth microdilution method2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
The BpeAB-OprB efflux pump of Burkholderia pseudomallei 1026b does not play a role in quorum sensing, virulence factor production, or extrusion of aminoglycosides but is a broad-spectrum drug efflux system.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588114Antimicrobial activity against Neisseria gonorrhoeae clinical isolates assessed as percent susceptible isolates after 24 hrs by agar dilution method2011Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2
Molecular analysis of antimicrobial resistance mechanisms in Neisseria gonorrhoeae isolates from Ontario, Canada.
AID718130Antimicrobial activity against Mycobacterium smegmatis str. MC2 155 by broth dilution method2012Journal of natural products, Dec-28, Volume: 75, Issue:12
Ramariolides A-D, antimycobacterial butenolides isolated from the mushroom Ramaria cystidiophora.
AID279897Antimicrobial activity against Burkholderia pseudomallei KHW in presence of 1000 uM chlorpromazine2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Synergistic interaction between phenothiazines and antimicrobial agents against Burkholderia pseudomallei.
AID212744Inhibition of telomerase before assembly using recombinant Tetraymena thermophilia TR and TERT at 50 uM2004Bioorganic & medicinal chemistry letters, Jul-05, Volume: 14, Issue:13
Nucleic acid-binding ligands identify new mechanisms to inhibit telomerase.
AID1241205Inhibition of pre-miR-372 (unknown origin) cleavage assessed as reduction of oncogenic microRNAs biogenesis by measuring fluorescence every minute for 5 hrs using 5'-FAM,3'-dabcyl-pre-miRNA beacons by FRET assay in presence of recombinant Dicer2015Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17
Ribosome-targeting antibiotics as inhibitors of oncogenic microRNAs biogenesis: Old scaffolds for new perspectives in RNA targeting.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1182153Ratio of MIC99 for Mycobacterium smegmatis to ratio of MIC99 for Mycobacterium smegmatis in presence of nor-chlorpromazine2014Bioorganic & medicinal chemistry, Aug-15, Volume: 22, Issue:16
Pharmacologically active metabolites, combination screening and target identification-driven drug repositioning in antituberculosis drug discovery.
AID212902Inhibition of human telomerase after assembly using recombinant hTR and hTERT at 50 uM2004Bioorganic & medicinal chemistry letters, Jul-05, Volume: 14, Issue:13
Nucleic acid-binding ligands identify new mechanisms to inhibit telomerase.
AID1241211Binding affinity to 5'-FAM-pre-miR-373 (unknown origin) after 4 hrs by fluorescence assay2015Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17
Ribosome-targeting antibiotics as inhibitors of oncogenic microRNAs biogenesis: Old scaffolds for new perspectives in RNA targeting.
AID279880Antimicrobial activity against Burkholderia pseudomallei KHW in presence of 7.8 uM promazine2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Synergistic interaction between phenothiazines and antimicrobial agents against Burkholderia pseudomallei.
AID1453426Antibacterial activity against Neisseria gonorrhoeae NCTC 12700/ATCC 49226 by two-fold serial dilution method2017Bioorganic & medicinal chemistry letters, 07-01, Volume: 27, Issue:13
Synthesis and biological evaluation of novel 5-aryl-4-(5-nitrofuran-2-yl)-pyrimidines as potential anti-bacterial agents.
AID322566Antibacterial activity against Pasteurella multocida isolate 12 with operon B,C 16S rRNA C1192G transversion mutation and S5 protein 32-SF-33>32I mutation by CLSI M31-A2 method2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Mutations in 16S rRNA and ribosomal protein S5 associated with high-level spectinomycin resistance in Pasteurella multocida.
AID279902Antimicrobial activity against Burkholderia pseudomallei KHW in presence of 31.3 uM chlorpromazine2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Synergistic interaction between phenothiazines and antimicrobial agents against Burkholderia pseudomallei.
AID1453433Antibacterial activity against Klebsiella pneumoniae ATCC 13883 by two-fold serial dilution method2017Bioorganic & medicinal chemistry letters, 07-01, Volume: 27, Issue:13
Synthesis and biological evaluation of novel 5-aryl-4-(5-nitrofuran-2-yl)-pyrimidines as potential anti-bacterial agents.
AID584328Antibacterial activity against gshB deficient Escherichia coli JW2914-12010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Interplay between drug efflux and antioxidants in Escherichia coli resistance to antibiotics.
AID279886Antimicrobial activity against Burkholderia pseudomallei KHW in presence of 62.5 uM omeprazole2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Synergistic interaction between phenothiazines and antimicrobial agents against Burkholderia pseudomallei.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID279888Antimicrobial activity against Burkholderia pseudomallei KHW in presence of 15.6 uM omeprazole2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Synergistic interaction between phenothiazines and antimicrobial agents against Burkholderia pseudomallei.
AID560222Antibacterial activity against Salmonella enterica serovar Typhimurium 01-4 by CLSI M7-A7 agar dilution method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Outer membrane protein STM3031 (Ail/OmpX-like protein) plays a key role in the ceftriaxone resistance of Salmonella enterica serovar Typhimurium.
AID279881Antimicrobial activity against Burkholderia pseudomallei KHW in presence of 3.9 uM promazine2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Synergistic interaction between phenothiazines and antimicrobial agents against Burkholderia pseudomallei.
AID279869Antimicrobial activity against Burkholderia pseudomallei KHW in presence of 31.3 uM prochlorperazine2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Synergistic interaction between phenothiazines and antimicrobial agents against Burkholderia pseudomallei.
AID428871Antibacterial activity against Escherichia coli CSH-2 by agar dilution method2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Novel plasmid-mediated 16S rRNA m1A1408 methyltransferase, NpmA, found in a clinically isolated Escherichia coli strain resistant to structurally diverse aminoglycosides.
AID279871Antimicrobial activity against Burkholderia pseudomallei KHW in presence of 7.8 uM prochlorperazine2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Synergistic interaction between phenothiazines and antimicrobial agents against Burkholderia pseudomallei.
AID396000Antimicrobial activity against Mycoplasma putrefaciens French isolates after 24 hrs by twofold serial dilution method2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
In vitro susceptibilities of Mycoplasma putrefaciens field isolates.
AID530846Antimicrobial activity against penicillin-,ofloxacin- and tetracyclin-resistant Neisseria gonorrhoeae multiantigen sequence type 2469 isolate 11 harboring penA gene by Etest2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Ceftibuten resistance and treatment failure of Neisseria gonorrhoeae infection.
AID1743161Antibacterial activity against Shigella flexneri2020European journal of medicinal chemistry, Dec-15, Volume: 208Multiple biological active 4-aminopyrazoles containing trifluoromethyl and their 4-nitroso-precursors: Synthesis and evaluation.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID534345Antimicrobial activity against Burkholderia pseudomallei Bp175 harboring mini-Tn7T-P1-bpeR+ after 24 hrs by broth microdilution method2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
The BpeAB-OprB efflux pump of Burkholderia pseudomallei 1026b does not play a role in quorum sensing, virulence factor production, or extrusion of aminoglycosides but is a broad-spectrum drug efflux system.
AID322561Antibacterial activity against Pasteurella multocida isolate 7 with operon A,B,C,D,E 16S rRNA C1192G transversion mutation by CLSI M31-A2 method2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Mutations in 16S rRNA and ribosomal protein S5 associated with high-level spectinomycin resistance in Pasteurella multocida.
AID1453430Antibacterial activity against Shigella flexneri RCPM 1a8516 by two-fold serial dilution method2017Bioorganic & medicinal chemistry letters, 07-01, Volume: 27, Issue:13
Synthesis and biological evaluation of novel 5-aryl-4-(5-nitrofuran-2-yl)-pyrimidines as potential anti-bacterial agents.
AID530051Antimicrobial activity against Staphylococcus aureus 286607-R1 harboring wild type gyrB by broth microdilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Discovery and characterization of QPT-1, the progenitor of a new class of bacterial topoisomerase inhibitors.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID532981Antibacterial activity against Escherichia coli DH5alpha2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
N-acetylcysteine-mediated modulation of bacterial antibiotic susceptibility.
AID1241202Inhibition of pre-miR-373 (unknown origin) cleavage assessed as reduction of oncogenic microRNAs biogenesis at 200 uM by measuring fluorescence every minute for 5 hrs using 5'-FAM,3'-dabcyl-pre-miRNA beacons by FRET assay in presence of recombinant Dicer2015Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17
Ribosome-targeting antibiotics as inhibitors of oncogenic microRNAs biogenesis: Old scaffolds for new perspectives in RNA targeting.
AID1743158Antibacterial activity against Citrobacter braakii2020European journal of medicinal chemistry, Dec-15, Volume: 208Multiple biological active 4-aminopyrazoles containing trifluoromethyl and their 4-nitroso-precursors: Synthesis and evaluation.
AID279867Antimicrobial activity against Burkholderia pseudomallei KHW in presence of 125 uM prochlorperazine2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Synergistic interaction between phenothiazines and antimicrobial agents against Burkholderia pseudomallei.
AID530837Antimicrobial activity against penicillin-,ofloxacin- and tetracyclin-resistant Neisseria gonorrhoeae multiantigen sequence type 835 isolate 2 harboring penA gene by Etest2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Ceftibuten resistance and treatment failure of Neisseria gonorrhoeae infection.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID530050Antimicrobial activity against Staphylococcus aureus 286607-R1 by broth microdilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Discovery and characterization of QPT-1, the progenitor of a new class of bacterial topoisomerase inhibitors.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID534342Antimicrobial activity against Burkholderia pseudomallei Bp58 harboring deleted bpeR::FRT gene after 24 hrs by broth microdilution method2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
The BpeAB-OprB efflux pump of Burkholderia pseudomallei 1026b does not play a role in quorum sensing, virulence factor production, or extrusion of aminoglycosides but is a broad-spectrum drug efflux system.
AID532987Antibacterial activity against Pseudomonas aeruginosa NCIM 5029 in presence of 10 mM N-Acetylcysteine2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
N-acetylcysteine-mediated modulation of bacterial antibiotic susceptibility.
AID1453429Antibacterial activity against Citrobacter braakii ATCC 101/57 by two-fold serial dilution method2017Bioorganic & medicinal chemistry letters, 07-01, Volume: 27, Issue:13
Synthesis and biological evaluation of novel 5-aryl-4-(5-nitrofuran-2-yl)-pyrimidines as potential anti-bacterial agents.
AID1241209Binding affinity to 5'-FAM-pre-miR-372 (unknown origin) after 4 hrs by fluorescence assay2015Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17
Ribosome-targeting antibiotics as inhibitors of oncogenic microRNAs biogenesis: Old scaffolds for new perspectives in RNA targeting.
AID1453442Toxicity in orally dosed mouse2017Bioorganic & medicinal chemistry letters, 07-01, Volume: 27, Issue:13
Synthesis and biological evaluation of novel 5-aryl-4-(5-nitrofuran-2-yl)-pyrimidines as potential anti-bacterial agents.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID428873Antibacterial activity against Escherichia coli JM109 carrying pMCL210 by agar dilution method2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Novel plasmid-mediated 16S rRNA m1A1408 methyltransferase, NpmA, found in a clinically isolated Escherichia coli strain resistant to structurally diverse aminoglycosides.
AID322563Antibacterial activity against Pasteurella multocida isolate 9 with operon B,C 16S rRNA C1192G transversion mutation and S5 protein 32-SF-33>32I mutation by CLSI M31-A2 method2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Mutations in 16S rRNA and ribosomal protein S5 associated with high-level spectinomycin resistance in Pasteurella multocida.
AID743656Antibacterial activity against Escherichia coli EB2120 conditional lolA strain with lolA deletion and complementing copy placed at araBAD locus at 1 to 256 ug/mL after 18 hrs in presence of 0.00002 to 0.2% of arabinose2013Bioorganic & medicinal chemistry letters, Apr-15, Volume: 23, Issue:8
Degradation of MAC13243 and studies of the interaction of resulting thiourea compounds with the lipoprotein targeting chaperone LolA.
AID477409Antibacterial activity against Staphylococcus aureus NCTC 8325 after 16 to 20 hrs by broth microdilution method2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Efflux-mediated bis-indole resistance in Staphylococcus aureus reveals differential substrate specificities for MepA and MepR.
AID1241201Inhibition of pre-miR-372 (unknown origin) cleavage assessed as reduction of oncogenic microRNAs biogenesis at 200 uM by measuring fluorescence every minute for 5 hrs using 5'-FAM,3'-dabcyl-pre-miRNA beacons by FRET assay in presence of recombinant Dicer2015Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17
Ribosome-targeting antibiotics as inhibitors of oncogenic microRNAs biogenesis: Old scaffolds for new perspectives in RNA targeting.
AID560224Antibacterial activity against Salmonella enterica serovar Typhimurium R200 expressing stm3031 gene deletion mutant by CLSI M7-A7 agar dilution method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Outer membrane protein STM3031 (Ail/OmpX-like protein) plays a key role in the ceftriaxone resistance of Salmonella enterica serovar Typhimurium.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID584329Antibacterial activity against gspS deficient Escherichia coli JW2956-12010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Interplay between drug efflux and antioxidants in Escherichia coli resistance to antibiotics.
AID322556Antibacterial activity against Pasteurella multocida isolate 2 with operon A,B,C,D,E,F 16S rRNA C1192G transversion mutation by CLSI M31-A2 method2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Mutations in 16S rRNA and ribosomal protein S5 associated with high-level spectinomycin resistance in Pasteurella multocida.
AID1241208Inhibition of pre-miR-21 (unknown origin) cleavage assessed as reduction of oncogenic microRNAs biogenesis by measuring fluorescence every minute for 5 hrs using 5'-FAM,3'-dabcyl-pre-miRNA beacons by FRET assay in presence of recombinant Dicer2015Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17
Ribosome-targeting antibiotics as inhibitors of oncogenic microRNAs biogenesis: Old scaffolds for new perspectives in RNA targeting.
AID1241203Inhibition of pre-miR-17 (unknown origin) cleavage assessed as reduction of oncogenic microRNAs biogenesis at 200 uM by measuring fluorescence every minute for 5 hrs using 5'-FAM,3'-dabcyl-pre-miRNA beacons by FRET assay in presence of recombinant Dicer2015Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17
Ribosome-targeting antibiotics as inhibitors of oncogenic microRNAs biogenesis: Old scaffolds for new perspectives in RNA targeting.
AID497731Inhibition of IPTG-stimulated Escherichia coli K-12 rpSR at 8 fold MIC by microarray analysis2009Nature chemical biology, Nov, Volume: 5, Issue:11
Chemical genomics in Escherichia coli identifies an inhibitor of bacterial lipoprotein targeting.
AID1743162Antibacterial activity against Pseudomonas aeruginosa2020European journal of medicinal chemistry, Dec-15, Volume: 208Multiple biological active 4-aminopyrazoles containing trifluoromethyl and their 4-nitroso-precursors: Synthesis and evaluation.
AID322570Antibacterial activity against Pasteurella multocida isolate 16 by CLSI M31-A2 method2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Mutations in 16S rRNA and ribosomal protein S5 associated with high-level spectinomycin resistance in Pasteurella multocida.
AID1182144Antitubercular activity against Mycobacterium smegmatis by checkerboard assay in presence of chlorpromazine sulfoxide2014Bioorganic & medicinal chemistry, Aug-15, Volume: 22, Issue:16
Pharmacologically active metabolites, combination screening and target identification-driven drug repositioning in antituberculosis drug discovery.
AID279876Antimicrobial activity against Burkholderia pseudomallei KHW in presence of 125 uM promazine2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Synergistic interaction between phenothiazines and antimicrobial agents against Burkholderia pseudomallei.
AID588119Antimicrobial activity against Neisseria gonorrhoeae clinical isolates after 24 hrs by agar dilution method2011Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2
Molecular analysis of antimicrobial resistance mechanisms in Neisseria gonorrhoeae isolates from Ontario, Canada.
AID279866Antimicrobial activity against Burkholderia pseudomallei KHW in presence of 250 uM prochlorperazine2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Synergistic interaction between phenothiazines and antimicrobial agents against Burkholderia pseudomallei.
AID65063Estimated rate of [3H]DHS (Dihydrostreptomycin) uptake in Escherichia coli K12 (ATCC 25868) [pmol/min (optical density unit)E-1] at the C50 was determined; NA is not applicable1987Journal of medicinal chemistry, Feb, Volume: 30, Issue:2
Comparison of aminoglycoside antibiotics with respect to uptake and lethal activity in Escherichia coli.
AID532988Antibacterial activity against Klebsiella aerogenes NCIM 22812010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
N-acetylcysteine-mediated modulation of bacterial antibiotic susceptibility.
AID322567Antibacterial activity against Pasteurella multocida isolate 13 with loss of 23K in S5 protein by CLSI M31-A2 method2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Mutations in 16S rRNA and ribosomal protein S5 associated with high-level spectinomycin resistance in Pasteurella multocida.
AID428869Antibacterial activity against Escherichia coli isolate ARS3 carrying pARS3 by agar dilution method2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Novel plasmid-mediated 16S rRNA m1A1408 methyltransferase, NpmA, found in a clinically isolated Escherichia coli strain resistant to structurally diverse aminoglycosides.
AID534344Antimicrobial activity against Burkholderia pseudomallei Bp174 harboring mini-Tn7T-bpeR+ after 24 hrs by broth microdilution method2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
The BpeAB-OprB efflux pump of Burkholderia pseudomallei 1026b does not play a role in quorum sensing, virulence factor production, or extrusion of aminoglycosides but is a broad-spectrum drug efflux system.
AID279887Antimicrobial activity against Burkholderia pseudomallei KHW in presence of 31.3 uM omeprazole2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Synergistic interaction between phenothiazines and antimicrobial agents against Burkholderia pseudomallei.
AID452742Antibacterial activity against Escherichia coli M15 containing pQE30 expression vector2010Bioorganic & medicinal chemistry letters, Jan-01, Volume: 20, Issue:1
Novel enoyl-ACP reductase (FabI) potential inhibitors of Escherichia coli from Chinese medicine monomers.
AID279879Antimicrobial activity against Burkholderia pseudomallei KHW in presence of 15.6 uM promazine2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Synergistic interaction between phenothiazines and antimicrobial agents against Burkholderia pseudomallei.
AID452744Antibacterial activity against Escherichia coli MG16552010Bioorganic & medicinal chemistry letters, Jan-01, Volume: 20, Issue:1
Novel enoyl-ACP reductase (FabI) potential inhibitors of Escherichia coli from Chinese medicine monomers.
AID497886Inhibition of IPTG-stimulated Escherichia coli K-12 yjeE at 4 fold MIC by microarray analysis2009Nature chemical biology, Nov, Volume: 5, Issue:11
Chemical genomics in Escherichia coli identifies an inhibitor of bacterial lipoprotein targeting.
AID1879068Antibacterial activity against NDM-1 positive Escherichia coli ZC-YN3 isolates assessed as inhibition of bacterial growth incubated for 18 to 24 hrs by CLSI based broth microdilution method2022European journal of medicinal chemistry, Mar-05, Volume: 231Metallo-β-lactamases inhibitor fisetin attenuates meropenem resistance in NDM-1-producing Escherichia coli.
AID428872Antibacterial activity against Escherichia coli JM109 carrying pMCL-BE by agar dilution method2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Novel plasmid-mediated 16S rRNA m1A1408 methyltransferase, NpmA, found in a clinically isolated Escherichia coli strain resistant to structurally diverse aminoglycosides.
AID532980Antibacterial activity against Escherichia coli DH5alpha in presence of 10 mM N-Acetylcysteine2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
N-acetylcysteine-mediated modulation of bacterial antibiotic susceptibility.
AID279903Antimicrobial activity against Burkholderia pseudomallei KHW in presence of 15.6 uM chlorpromazine2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Synergistic interaction between phenothiazines and antimicrobial agents against Burkholderia pseudomallei.
AID509632Antimicrobial activity against Staphylococcus aureus 25 transformant carrying plasmid pKKS25 and expressing erm(T), dfrKtet(L), tet(K), tet(M), mecA and blaZ genes by broth microdilution method2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Identification of a plasmid-borne resistance gene cluster comprising the resistance genes erm(T), dfrK, and tet(L) in a porcine methicillin-resistant Staphylococcus aureus ST398 strain.
AID575169Inhibition of acrAB AcrAB-TolC-mediated Nile Red efflux in Escherichia coli K-12 3-AG100 overexpressing acrAB AcrAB-TolC assessed as time needed for 50% efflux after energization with 50 mM glucose at 1000 uM by spectrofluorometric assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Optimized Nile Red efflux assay of AcrAB-TolC multidrug efflux system shows competition between substrates.
AID584330Antibacterial activity against ygiBC, yjfMC, gspS deficient Escherichia coli GD1082010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Interplay between drug efflux and antioxidants in Escherichia coli resistance to antibiotics.
AID279899Antimicrobial activity against Burkholderia pseudomallei KHW in presence of 250 uM chlorpromazine2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Synergistic interaction between phenothiazines and antimicrobial agents against Burkholderia pseudomallei.
AID396001Antimicrobial activity against Mycoplasma putrefaciens Jordanian isolates after 24 hrs by twofold serial dilution method2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
In vitro susceptibilities of Mycoplasma putrefaciens field isolates.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID584325Antibacterial activity against wild type Escherichia coli BW251132010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Interplay between drug efflux and antioxidants in Escherichia coli resistance to antibiotics.
AID325444Antibacterial activity against Escherichia coli K12 after 14 to 16 hrs by broth dilution method2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Polyamine effects on antibiotic susceptibility in bacteria.
AID322569Antibacterial activity against Pasteurella multocida isolate 15 by CLSI M31-A2 method2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Mutations in 16S rRNA and ribosomal protein S5 associated with high-level spectinomycin resistance in Pasteurella multocida.
AID530841Antimicrobial activity against penicillin-,ofloxacin- and tetracyclin-resistant Neisseria gonorrhoeae multiantigen sequence type 835 isolate 6 harboring penA gene by Etest2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Ceftibuten resistance and treatment failure of Neisseria gonorrhoeae infection.
AID322559Antibacterial activity against Pasteurella multocida isolate 5 with operon A,B,C,D,E,F 16S rRNA C1192G transversion mutation by CLSI M31-A2 method2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Mutations in 16S rRNA and ribosomal protein S5 associated with high-level spectinomycin resistance in Pasteurella multocida.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1453428Antibacterial activity against Escherichia coli ATCC 8739 by two-fold serial dilution method2017Bioorganic & medicinal chemistry letters, 07-01, Volume: 27, Issue:13
Synthesis and biological evaluation of novel 5-aryl-4-(5-nitrofuran-2-yl)-pyrimidines as potential anti-bacterial agents.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID532984Antibacterial activity against Escherichia coli MG1655 in presence of 10 mM N-Acetylcysteine2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
N-acetylcysteine-mediated modulation of bacterial antibiotic susceptibility.
AID279905Antimicrobial activity against Burkholderia pseudomallei KHW in presence of 3.9 uM chlorpromazine2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Synergistic interaction between phenothiazines and antimicrobial agents against Burkholderia pseudomallei.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID530842Antimicrobial activity against penicillin-,ofloxacin- and tetracyclin-resistant Neisseria gonorrhoeae multiantigen sequence type 835 isolate 7 harboring penA gene by Etest2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Ceftibuten resistance and treatment failure of Neisseria gonorrhoeae infection.
AID530845Antimicrobial activity against penicillin-,ofloxacin- and tetracyclin-resistant Neisseria gonorrhoeae multiantigen sequence type 835 isolate 10 harboring penA gene by Etest2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Ceftibuten resistance and treatment failure of Neisseria gonorrhoeae infection.
AID428870Antibacterial activity against Escherichia coli CSH-2 carrying Escherichia coli ARS3 pARS3 by agar dilution method2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Novel plasmid-mediated 16S rRNA m1A1408 methyltransferase, NpmA, found in a clinically isolated Escherichia coli strain resistant to structurally diverse aminoglycosides.
AID532990Antibacterial activity against Klebsiella pneumoniae NCIM 2883 assessed as growth inhibition in presence of 10 mM N-Acetylcysteine2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
N-acetylcysteine-mediated modulation of bacterial antibiotic susceptibility.
AID325446Antibacterial activity against Salmonella enterica serovar Typhimurium LT2 after 14 to 16 hrs by broth dilution method2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Polyamine effects on antibiotic susceptibility in bacteria.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID497730Inhibition of IPTG-stimulated Escherichia coli K-12 yjeE at 8 fold MIC by microarray analysis2009Nature chemical biology, Nov, Volume: 5, Issue:11
Chemical genomics in Escherichia coli identifies an inhibitor of bacterial lipoprotein targeting.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1182136Antitubercular activity against Mycobacterium smegmatis by checkerboard assay in presence of chlorpromazine2014Bioorganic & medicinal chemistry, Aug-15, Volume: 22, Issue:16
Pharmacologically active metabolites, combination screening and target identification-driven drug repositioning in antituberculosis drug discovery.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID534341Antimicrobial activity against Burkholderia pseudomallei Bp227 harboring deleted (bpeAB-oprA)::FRT gene after 24 hrs by broth microdilution method2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
The BpeAB-OprB efflux pump of Burkholderia pseudomallei 1026b does not play a role in quorum sensing, virulence factor production, or extrusion of aminoglycosides but is a broad-spectrum drug efflux system.
AID1182131Antitubercular activity against Mycobacterium smegmatis by checkerboard assay2014Bioorganic & medicinal chemistry, Aug-15, Volume: 22, Issue:16
Pharmacologically active metabolites, combination screening and target identification-driven drug repositioning in antituberculosis drug discovery.
AID1453427Antibacterial activity against gonorrhea patient derived azithromycin resistant-Neisseria gonorrhoeae by two-fold serial dilution method2017Bioorganic & medicinal chemistry letters, 07-01, Volume: 27, Issue:13
Synthesis and biological evaluation of novel 5-aryl-4-(5-nitrofuran-2-yl)-pyrimidines as potential anti-bacterial agents.
AID532983Antibacterial activity against Escherichia coli W31102010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
N-acetylcysteine-mediated modulation of bacterial antibiotic susceptibility.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID279884Antimicrobial activity against Burkholderia pseudomallei KHW in presence of 250 uM omeprazole2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Synergistic interaction between phenothiazines and antimicrobial agents against Burkholderia pseudomallei.
AID1182145Antitubercular activity against Mycobacterium smegmatis by checkerboard assay in presence of nor-chlorpromazine sulfoxide2014Bioorganic & medicinal chemistry, Aug-15, Volume: 22, Issue:16
Pharmacologically active metabolites, combination screening and target identification-driven drug repositioning in antituberculosis drug discovery.
AID279904Antimicrobial activity against Burkholderia pseudomallei KHW in presence of 7.8 uM chlorpromazine2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Synergistic interaction between phenothiazines and antimicrobial agents against Burkholderia pseudomallei.
AID534339Antimicrobial activity against Burkholderia pseudomallei 1026b after 24 hrs by broth microdilution method2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
The BpeAB-OprB efflux pump of Burkholderia pseudomallei 1026b does not play a role in quorum sensing, virulence factor production, or extrusion of aminoglycosides but is a broad-spectrum drug efflux system.
AID1182147Ratio of MIC99 for Mycobacterium smegmatis to ratio of MIC99 for Mycobacterium smegmatis in presence of chlorpromazine2014Bioorganic & medicinal chemistry, Aug-15, Volume: 22, Issue:16
Pharmacologically active metabolites, combination screening and target identification-driven drug repositioning in antituberculosis drug discovery.
AID1182142Antitubercular activity against Mycobacterium smegmatis by checkerboard assay in presence of nor-chlorpromazine2014Bioorganic & medicinal chemistry, Aug-15, Volume: 22, Issue:16
Pharmacologically active metabolites, combination screening and target identification-driven drug repositioning in antituberculosis drug discovery.
AID283646Susceptibility of Escherichia coli K12 MG1655 by agar dilution method2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Effects of glutathione and ascorbic acid on streptomycin sensitivity of Escherichia coli.
AID452745Antibacterial activity against Escherichia coli M152010Bioorganic & medicinal chemistry letters, Jan-01, Volume: 20, Issue:1
Novel enoyl-ACP reductase (FabI) potential inhibitors of Escherichia coli from Chinese medicine monomers.
AID584331Antibacterial activity against tolC, speE deficient Escherichia coli GD1062010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Interplay between drug efflux and antioxidants in Escherichia coli resistance to antibiotics.
AID1182151Ratio of MIC99 for Mycobacterium smegmatis to ratio of MIC99 for Mycobacterium smegmatis in presence of 7-hydroxy chlorpromazine2014Bioorganic & medicinal chemistry, Aug-15, Volume: 22, Issue:16
Pharmacologically active metabolites, combination screening and target identification-driven drug repositioning in antituberculosis drug discovery.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID644960Displacement of ethidium bromide from human pre-hsa-mir-155 miRNA after 30 mins2012Bioorganic & medicinal chemistry letters, Feb-15, Volume: 22, Issue:4
Pre-microRNA binding aminoglycosides and antitumor drugs as inhibitors of Dicer catalyzed microRNA processing.
AID279863Antimicrobial activity against Burkholderia pseudomallei KHW2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Synergistic interaction between phenothiazines and antimicrobial agents against Burkholderia pseudomallei.
AID575170Inhibition of acrAB AcrAB-TolC-mediated Nile Red efflux in Escherichia coli K-12 3-AG100 overexpressing acrAB AcrAB-TolC assessed as time needed for 50% efflux after energization with 50 mM glucose at 200 uM by spectrofluorometric assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Optimized Nile Red efflux assay of AcrAB-TolC multidrug efflux system shows competition between substrates.
AID322568Antibacterial activity against Pasteurella multocida isolate 14 by CLSI M31-A2 method2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Mutations in 16S rRNA and ribosomal protein S5 associated with high-level spectinomycin resistance in Pasteurella multocida.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID532982Antibacterial activity against Escherichia coli W3110 in presence of 10 mM N-Acetylcysteine2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
N-acetylcysteine-mediated modulation of bacterial antibiotic susceptibility.
AID1182139Antitubercular activity against Mycobacterium smegmatis assessed as reduction in MIC99 by checkerboard assay in presence of nor-chlorpromazine sulfoxide relative to control2014Bioorganic & medicinal chemistry, Aug-15, Volume: 22, Issue:16
Pharmacologically active metabolites, combination screening and target identification-driven drug repositioning in antituberculosis drug discovery.
AID534346Antimicrobial activity against Burkholderia pseudomallei Bp207 harboring deleted (bpeAB-oprA)::FRT gene after 24 hrs by broth microdilution method2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
The BpeAB-OprB efflux pump of Burkholderia pseudomallei 1026b does not play a role in quorum sensing, virulence factor production, or extrusion of aminoglycosides but is a broad-spectrum drug efflux system.
AID279875Antimicrobial activity against Burkholderia pseudomallei KHW in presence of 250 uM promazine2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Synergistic interaction between phenothiazines and antimicrobial agents against Burkholderia pseudomallei.
AID509630Antimicrobial activity against Staphylococcus aureus RN4220 by broth microdilution method2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Identification of a plasmid-borne resistance gene cluster comprising the resistance genes erm(T), dfrK, and tet(L) in a porcine methicillin-resistant Staphylococcus aureus ST398 strain.
AID452746Antibacterial activity against fabI-overexpressing Escherichia coli M152010Bioorganic & medicinal chemistry letters, Jan-01, Volume: 20, Issue:1
Novel enoyl-ACP reductase (FabI) potential inhibitors of Escherichia coli from Chinese medicine monomers.
AID532985Antibacterial activity against Escherichia coli MG16552010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
N-acetylcysteine-mediated modulation of bacterial antibiotic susceptibility.
AID325447Antibacterial activity against Staphylococcus aureus N315 after 14 to 16 hrs by broth dilution method2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Polyamine effects on antibiotic susceptibility in bacteria.
AID283648Susceptibility of Escherichia coli K12 MG1655 in presence of 10 mM glutathione by agar dilution method relative to control2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Effects of glutathione and ascorbic acid on streptomycin sensitivity of Escherichia coli.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID534340Antimicrobial activity against Burkholderia pseudomallei Bp50 harboring deleted (amrRAB-oprA)::FRT gene after 24 hrs by broth microdilution method2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
The BpeAB-OprB efflux pump of Burkholderia pseudomallei 1026b does not play a role in quorum sensing, virulence factor production, or extrusion of aminoglycosides but is a broad-spectrum drug efflux system.
AID279885Antimicrobial activity against Burkholderia pseudomallei KHW in presence of 125 uM omeprazole2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Synergistic interaction between phenothiazines and antimicrobial agents against Burkholderia pseudomallei.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID279874Antimicrobial activity against Burkholderia pseudomallei KHW in presence of 500 uM promazine2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Synergistic interaction between phenothiazines and antimicrobial agents against Burkholderia pseudomallei.
AID588208Literature-mined public compounds from Lowe et al phospholipidosis modelling dataset2010Molecular pharmaceutics, Oct-04, Volume: 7, Issue:5
Predicting phospholipidosis using machine learning.
AID1482267Antibacterial activity against Escherichia coli MG1655 measured every 15 mins for 12 hrs2017Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9
Prediction of Antibiotic Interactions Using Descriptors Derived from Molecular Structure.
AID279872Antimicrobial activity against Burkholderia pseudomallei KHW in presence of 3.9 uM prochlorperazine2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Synergistic interaction between phenothiazines and antimicrobial agents against Burkholderia pseudomallei.
AID279890Antimicrobial activity against Burkholderia pseudomallei KHW in presence of 3.9 uM omeprazole2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Synergistic interaction between phenothiazines and antimicrobial agents against Burkholderia pseudomallei.
AID530843Antimicrobial activity against penicillin-,ofloxacin- and tetracyclin-resistant Neisseria gonorrhoeae multiantigen sequence type 835 isolate 8 harboring penA gene by Etest2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Ceftibuten resistance and treatment failure of Neisseria gonorrhoeae infection.
AID322555Antibacterial activity against Pasteurella multocida isolate 1 with operon A,B,C,D,E,F 16S rRNA C1192G transversion mutation by CLSI M31-A2 method2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Mutations in 16S rRNA and ribosomal protein S5 associated with high-level spectinomycin resistance in Pasteurella multocida.
AID325448Antibacterial activity against Staphylococcus aureus Mu50 after 14 to 16 hrs by broth dilution method2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Polyamine effects on antibiotic susceptibility in bacteria.
AID212903Inhibition of human telomerase before assembly using recombinant hTR and hTERT at 50 uM2004Bioorganic & medicinal chemistry letters, Jul-05, Volume: 14, Issue:13
Nucleic acid-binding ligands identify new mechanisms to inhibit telomerase.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID279865Antimicrobial activity against Burkholderia pseudomallei KHW in presence of 500 uM prochlorperazine2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Synergistic interaction between phenothiazines and antimicrobial agents against Burkholderia pseudomallei.
AID588113Antimicrobial activity against Neisseria gonorrhoeae clinical isolates assessed as percent resistant isolates after 24 hrs by agar dilution method2011Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2
Molecular analysis of antimicrobial resistance mechanisms in Neisseria gonorrhoeae isolates from Ontario, Canada.
AID279882Antimicrobial activity against Burkholderia pseudomallei KHW in presence of 1000 uM omeprazole2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Synergistic interaction between phenothiazines and antimicrobial agents against Burkholderia pseudomallei.
AID322571Antibacterial activity against Pasteurella multocida isolate 17 by CLSI M31-A2 method2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Mutations in 16S rRNA and ribosomal protein S5 associated with high-level spectinomycin resistance in Pasteurella multocida.
AID396002Antimicrobial activity against Mycoplasma putrefaciens KS1 after 24 hrs by twofold serial dilution method2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
In vitro susceptibilities of Mycoplasma putrefaciens field isolates.
AID279878Antimicrobial activity against Burkholderia pseudomallei KHW in presence of 31.3 uM promazine2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Synergistic interaction between phenothiazines and antimicrobial agents against Burkholderia pseudomallei.
AID212743Inhibition of telomerase after assembly using recombinant Tetraymena thermophilia TR and TERT at 50 uM2004Bioorganic & medicinal chemistry letters, Jul-05, Volume: 14, Issue:13
Nucleic acid-binding ligands identify new mechanisms to inhibit telomerase.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID497888Inhibition of IPTG-stimulated Escherichia coli K-12 rpSR at 4 fold MIC by microarray analysis2009Nature chemical biology, Nov, Volume: 5, Issue:11
Chemical genomics in Escherichia coli identifies an inhibitor of bacterial lipoprotein targeting.
AID279889Antimicrobial activity against Burkholderia pseudomallei KHW in presence of 7.8 uM omeprazole2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Synergistic interaction between phenothiazines and antimicrobial agents against Burkholderia pseudomallei.
AID325449Antibacterial activity against Staphylococcus aureus ATCC 3556 after 14 to 16 hrs by broth dilution method2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Polyamine effects on antibiotic susceptibility in bacteria.
AID279883Antimicrobial activity against Burkholderia pseudomallei KHW in presence of 500 uM omeprazole2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Synergistic interaction between phenothiazines and antimicrobial agents against Burkholderia pseudomallei.
AID1453435Antibacterial activity against Staphylococcus aureus ATCC 25923 by two-fold serial dilution method2017Bioorganic & medicinal chemistry letters, 07-01, Volume: 27, Issue:13
Synthesis and biological evaluation of novel 5-aryl-4-(5-nitrofuran-2-yl)-pyrimidines as potential anti-bacterial agents.
AID1743156Antibacterial activity against Escherichia coli2020European journal of medicinal chemistry, Dec-15, Volume: 208Multiple biological active 4-aminopyrazoles containing trifluoromethyl and their 4-nitroso-precursors: Synthesis and evaluation.
AID1743157Antibacterial activity against Klebsiella pneumoniae2020European journal of medicinal chemistry, Dec-15, Volume: 208Multiple biological active 4-aminopyrazoles containing trifluoromethyl and their 4-nitroso-precursors: Synthesis and evaluation.
AID1182143Antitubercular activity against Mycobacterium smegmatis by checkerboard assay in presence of chlorpromazine-N-S-dioxide2014Bioorganic & medicinal chemistry, Aug-15, Volume: 22, Issue:16
Pharmacologically active metabolites, combination screening and target identification-driven drug repositioning in antituberculosis drug discovery.
AID1743159Antibacterial activity against Proteus vulgaris2020European journal of medicinal chemistry, Dec-15, Volume: 208Multiple biological active 4-aminopyrazoles containing trifluoromethyl and their 4-nitroso-precursors: Synthesis and evaluation.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID477411Antibacterial activity against MBX-1090-resistant Staphylococcus aureus isolate d20A1 after 16 to 20 hrs by broth microdilution method2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Efflux-mediated bis-indole resistance in Staphylococcus aureus reveals differential substrate specificities for MepA and MepR.
AID1453439Cytotoxicity against mouse MacCoy B cells after 24 hrs by p-Nitro-Blue tetrazolium chloride dye based colorometric method2017Bioorganic & medicinal chemistry letters, 07-01, Volume: 27, Issue:13
Synthesis and biological evaluation of novel 5-aryl-4-(5-nitrofuran-2-yl)-pyrimidines as potential anti-bacterial agents.
AID279877Antimicrobial activity against Burkholderia pseudomallei KHW in presence of 62.5 uM promazine2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Synergistic interaction between phenothiazines and antimicrobial agents against Burkholderia pseudomallei.
AID532989Antibacterial activity against Klebsiella aerogenes NCIM 2281 in presence of 10 mM N-Acetylcysteine2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
N-acetylcysteine-mediated modulation of bacterial antibiotic susceptibility.
AID1453434Antibacterial activity against Pseudomonas aeruginosa ATCC 9027 by two-fold serial dilution method2017Bioorganic & medicinal chemistry letters, 07-01, Volume: 27, Issue:13
Synthesis and biological evaluation of novel 5-aryl-4-(5-nitrofuran-2-yl)-pyrimidines as potential anti-bacterial agents.
AID1241207Inhibition of pre-miR-373 (unknown origin) cleavage assessed as reduction of oncogenic microRNAs biogenesis by measuring fluorescence every minute for 5 hrs using 5'-FAM,3'-dabcyl-pre-miRNA beacons by FRET assay in presence of recombinant Dicer2015Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17
Ribosome-targeting antibiotics as inhibitors of oncogenic microRNAs biogenesis: Old scaffolds for new perspectives in RNA targeting.
AID1743160Antibacterial activity against Serratia marcescens2020European journal of medicinal chemistry, Dec-15, Volume: 208Multiple biological active 4-aminopyrazoles containing trifluoromethyl and their 4-nitroso-precursors: Synthesis and evaluation.
AID1743155Antibacterial activity against Neisseria gonorrhoeae2020European journal of medicinal chemistry, Dec-15, Volume: 208Multiple biological active 4-aminopyrazoles containing trifluoromethyl and their 4-nitroso-precursors: Synthesis and evaluation.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID279900Antimicrobial activity against Burkholderia pseudomallei KHW in presence of 125 uM chlorpromazine2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Synergistic interaction between phenothiazines and antimicrobial agents against Burkholderia pseudomallei.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1453431Antibacterial activity against Proteus vulgaris RCPM 160125 (222) by two-fold serial dilution method2017Bioorganic & medicinal chemistry letters, 07-01, Volume: 27, Issue:13
Synthesis and biological evaluation of novel 5-aryl-4-(5-nitrofuran-2-yl)-pyrimidines as potential anti-bacterial agents.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID588220Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset2008Toxicology mechanisms and methods, , Volume: 18, Issue:2-3
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID532986Antibacterial activity against Pseudomonas aeruginosa NCIM 50292010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
N-acetylcysteine-mediated modulation of bacterial antibiotic susceptibility.
AID534337Antimicrobial activity against Burkholderia pseudomallei Bp216 harboring mini-Tn7T after 24 hrs by broth microdilution method2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
The BpeAB-OprB efflux pump of Burkholderia pseudomallei 1026b does not play a role in quorum sensing, virulence factor production, or extrusion of aminoglycosides but is a broad-spectrum drug efflux system.
AID1241206Inhibition of pre-miR-17 (unknown origin) cleavage assessed as reduction of oncogenic microRNAs biogenesis by measuring fluorescence every minute for 5 hrs using 5'-FAM,3'-dabcyl-pre-miRNA beacons by FRET assay in presence of recombinant Dicer2015Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17
Ribosome-targeting antibiotics as inhibitors of oncogenic microRNAs biogenesis: Old scaffolds for new perspectives in RNA targeting.
AID1879067Antibacterial activity against pET28a-NDM-1 positive Escherichia coli BL21(DE3) isolates assessed as inhibition of bacterial growth incubated for 18 to 24 hrs by CLSI based broth microdilution method2022European journal of medicinal chemistry, Mar-05, Volume: 231Metallo-β-lactamases inhibitor fisetin attenuates meropenem resistance in NDM-1-producing Escherichia coli.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID584332Antibacterial activity against tolC, gshB deficient Escherichia coli GD1072010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Interplay between drug efflux and antioxidants in Escherichia coli resistance to antibiotics.
AID322562Antibacterial activity against Pasteurella multocida isolate 8 with operon A,B,C,D,E 16S rRNA C1192G transversion mutation by CLSI M31-A2 method2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Mutations in 16S rRNA and ribosomal protein S5 associated with high-level spectinomycin resistance in Pasteurella multocida.
AID322557Antibacterial activity against Pasteurella multocida isolate 3 with operon A,B,C,D,E,F 16S rRNA C1192G transversion mutation by CLSI M31-A2 method2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Mutations in 16S rRNA and ribosomal protein S5 associated with high-level spectinomycin resistance in Pasteurella multocida.
AID1241210Binding affinity to 5'-FAM-pre-miR-17 (unknown origin) after 4 hrs by fluorescence assay2015Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17
Ribosome-targeting antibiotics as inhibitors of oncogenic microRNAs biogenesis: Old scaffolds for new perspectives in RNA targeting.
AID584326Antibacterial activity against tolC deficient Escherichia coli GD1002010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Interplay between drug efflux and antioxidants in Escherichia coli resistance to antibiotics.
AID560223Antibacterial activity against Salmonella enterica serovar Typhimurium R200 expressing Outer membrane protein STM3031 by CLSI M7-A7 agar dilution method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Outer membrane protein STM3031 (Ail/OmpX-like protein) plays a key role in the ceftriaxone resistance of Salmonella enterica serovar Typhimurium.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID279898Antimicrobial activity against Burkholderia pseudomallei KHW in presence of 500 uM chlorpromazine2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Synergistic interaction between phenothiazines and antimicrobial agents against Burkholderia pseudomallei.
AID1356822Inhibition of bacterial protein synthesis in cell-free Escherichia coli incubated for 1 hr and measured for every 20 mins by bacterial cell-free transcription-translation assay2018Journal of medicinal chemistry, 09-13, Volume: 61, Issue:17
Total Synthesis and Structure-Activity Relationships Study of Odilorhabdins, a New Class of Peptides Showing Potent Antibacterial Activity.
AID530844Antimicrobial activity against penicillin-,ofloxacin- and tetracyclin-resistant Neisseria gonorrhoeae multiantigen sequence type 835 isolate 9 harboring penA gene by Etest2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Ceftibuten resistance and treatment failure of Neisseria gonorrhoeae infection.
AID534338Antimicrobial activity against Burkholderia pseudomallei Bp250 harboring mini-Tn7T-bpeA+B+ -oprB+ after 24 hrs by broth microdilution method2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
The BpeAB-OprB efflux pump of Burkholderia pseudomallei 1026b does not play a role in quorum sensing, virulence factor production, or extrusion of aminoglycosides but is a broad-spectrum drug efflux system.
AID279868Antimicrobial activity against Burkholderia pseudomallei KHW in presence of 62.5 uM prochlorperazine2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Synergistic interaction between phenothiazines and antimicrobial agents against Burkholderia pseudomallei.
AID1453432Antibacterial activity against Serratia marcescens ATCC 13880 by two-fold serial dilution method2017Bioorganic & medicinal chemistry letters, 07-01, Volume: 27, Issue:13
Synthesis and biological evaluation of novel 5-aryl-4-(5-nitrofuran-2-yl)-pyrimidines as potential anti-bacterial agents.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID530838Antimicrobial activity against penicillin-,ofloxacin- and tetracyclin-resistant Neisseria gonorrhoeae multiantigen sequence type 835 isolate 3 harboring penA gene by Etest2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Ceftibuten resistance and treatment failure of Neisseria gonorrhoeae infection.
AID529885Antibacterial activity against Staphylococcus aureus RN4220 by broth microdilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Discovery and characterization of QPT-1, the progenitor of a new class of bacterial topoisomerase inhibitors.
AID530836Antimicrobial activity against penicillin-,ofloxacin- and tetracyclin-resistant Neisseria gonorrhoeae multiantigen sequence type 835 isolate 1 harboring penA gene by Etest2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Ceftibuten resistance and treatment failure of Neisseria gonorrhoeae infection.
AID279864Antimicrobial activity against Burkholderia pseudomallei KHW in presence of 1000 uM prochlorperazine2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Synergistic interaction between phenothiazines and antimicrobial agents against Burkholderia pseudomallei.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,210)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990692 (57.19)18.7374
1990's158 (13.06)18.2507
2000's154 (12.73)29.6817
2010's162 (13.39)24.3611
2020's44 (3.64)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 54.64

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index54.64 (24.57)
Research Supply Index7.24 (2.92)
Research Growth Index4.44 (4.65)
Search Engine Demand Index102.27 (26.88)
Search Engine Supply Index2.19 (0.95)

This Compound (54.64)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials87 (6.63%)5.53%
Reviews48 (3.66%)6.00%
Case Studies32 (2.44%)4.05%
Observational0 (0.00%)0.25%
Other1,145 (87.27%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Prospective Randomized Study to Compare Clinical Outcomes in Patients With Osteomyelitis Treated With Intravenous Antibiotics Versus Intravenous Antibiotics With an Early Switch to Oral Antibiotics [NCT02099240]Early Phase 111 participants (Actual)Interventional2014-03-06Terminated(stopped due to Not enough patient enrollment and lack of staffing)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]